

Title (en)

METHODS OF DETECTING RESPONSES TO THERAPIES USING PERFORIN LEVELS

Title (de)

VERFAHREN ZUR ERKENNUNG DES ANSPRECHENS AUF THERAPIEN UNTER VERWENDUNG VON PERFORINSPIEGELN

Title (fr)

PROCÉDÉS DE DÉTECTION DE RÉPONSES À DES THÉRAPIES UTILISANT LES NIVEAUX DE PERFORINE

Publication

EP 2464741 A4 20130522 (EN)

Application

EP 10808602 A 20100809

Priority

- US 23260509 P 20090810
- US 2010044921 W 20100809

Abstract (en)

[origin: WO2011019670A1] Methods and kits for detecting positive responses to therapies, diagnosing a disease or condition, and detecting impending clinical relapse. The method may feature obtaining a sample from a patient and either detecting a percentage of perforin+ natural killer (NK) cells or detecting a level of perforin expression in the sample. Positive responses to the therapy may be detected if the percentage of perforins NK cells is greater than or equal to about 75% of total NK cells or if the level of perforin expression in the sample is within a level of perforin expression in a normal sample +/-25%. The disease or condition or impending clinical relapse may be detected if the level of perforin expression in the sample is less than a level of perforin expression in a normal sample minus about 25% or the percentage of perforin+ NK cells is less than about 75% of total NK cells.

IPC 8 full level

G01N 33/68 (2006.01)

CPC (source: EP)

G01N 33/6896 (2013.01); **G01N 2333/70535** (2013.01); **G01N 2800/285** (2013.01); **G01N 2800/52** (2013.01); **G01N 2800/54** (2013.01); **G01N 2800/56** (2013.01)

Citation (search report)

- [X] US 2007048264 A1 20070301 - KINDSVOGEL WAYNE R [US], et al
- [X] GORDANA RUBESA ET AL: "Increased perforin expression in multiple sclerosis patients during exacerbation of disease in peripheral blood lymphocytes", JOURNAL OF NEUROIMMUNOLOGY, vol. 74, no. 1-2, 1 April 1997 (1997-04-01), pages 198 - 204, XP055057332, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(96)00236-6
- [X] RATTS R B ET AL: "CD28<->CD57<+> T cells predominate in CD8 responses to glatiramer acetate", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 178, no. 1-2, 1 September 2006 (2006-09-01), pages 117 - 129, XP027901498, ISSN: 0165-5728
- [A] AL-FALAHI, Y., ET AL: "Splenic natural killer cell activity in two models of experimental neurodegenerative diseases", J. CELL. MOL. MED., vol. 13, no. 8B, 29 December 2008 (2008-12-29), pages 2693 - 2703, XP002694229
- [T] NAYAK, R.C. AND JACOLIK, R.F.: "CD16+/Perforin+ Lymphocytes (NK Cells) Regulate Autoimmunity in Multiple Sclerosis by Cytolysis of Antigen Laden Cells in the Peripheral Blood", 20 April 2012 (2012-04-20), XP002694230, Retrieved from the Internet <URL:<http://www.msdx.co/assets/docs/2012%20NK%20Conference%20-%20NK%20Cells%20and%20MS.pdf>> [retrieved on 20130318]
- See references of WO 2011019670A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

Designated extension state (EPC)

BA ME RS

DOCDB simple family (publication)

WO 2011019670 A1 20110217; CA 2770680 A1 20110217; EP 2464741 A1 20120620; EP 2464741 A4 20130522

DOCDB simple family (application)

US 2010044921 W 20100809; CA 2770680 A 20100809; EP 10808602 A 20100809